Fig. 1From: Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancerRelapse-free survival curves by PAM50 classification. Relapse-free survival curves were evaluated in patients according to the PAM50 classification up to 120 months post-surgery. The log-rank test was used to evaluate statistical differencesBack to article page